BioSpace News Archive

Lone Star Bio

Marker Therapeutics Receives Approval from United States Adopted Name (USAN) Council and International Nonproprietary Names (INN) Expert Committee for “Neldaleucel” as Nonproprietary Name for MT-601

Marker Therapeutics, Inc. announced today that the United States Adopted Names (USAN) Council, and the World Health Organization (WHO) International Nonproprietary Names (INN) expert committee has approved “ neldaleucel ” as the nonproprietary (generic) name for MT-601, a multi-tumor associated antigen (multiTAA)-specific T cell product candidate for the treatment of patients with lymphoma.

January 22, 2024
·
5 min read
Pharm Country

Amarin Chairman & CEO Issue Letter to Shareholders - Jan 22, 2024

Amarin Corporation plc announced that the Company’s Chairman of the Board, Odysseas Kostas, M.D., and President & CEO, Patrick Holt, issued the following letter to Amarin shareholders.

January 22, 2024
·
5 min read
Business

CENTENE CORPORATION ANNOUNCES APPOINTMENT OF MICHAEL A. CARSON AS PRESIDENT AND CHIEF EXECUTIVE OFFICER OF ITS MEDICARE BUSINESS

Centene Corporation today announced two appointments. Michael A. Carson joins Centene as President and Chief Executive Officer (CEO) of its Medicare business, Wellcare.

January 22, 2024
·
10 min read
Business

Elevation Oncology Announces Appointment of Darcy Mootz, Ph.D., to its Board of Directors

Elevation Oncology, Inc. today announced the appointment of Darcy Mootz, Ph.D., to its Board of Directors.

January 22, 2024
·
5 min read
BioMidwest

Surmodics Announces Successful Early Clinical Use of Pounce™ LP (Low Profile) Thrombectomy System, Designed to Address a Critical, Unmet Need by Facilitating Removal of Thrombi and Emboli Below the Knee

Surmodics, Inc. today announced successful early clinical use of the company’s Pounce™ LP (Low Profile) Thrombectomy System.

January 22, 2024
·
6 min read
Genetown

Botensilimab/Balstilimab Breakthrough Data Presented at ASCO-GI Shows Unprecedented Tumor Shrinkage and Robust Biomarker Response in Prevalent Colorectal Cancer Population

Botensilimab/Balstilimab (BOT/BAL) shows major tumor regression in 67.5% of Patients with Localized MSS Colorectal Cancer (CRC), a tumor typically unresponsive to IO therapy.

January 22, 2024
·
5 min read
Pharm Country

YPrime Unveils a Transformative Brand Focused on Solving for Certainty in Clinical Trials

YPrime today announced a bold brand evolution initiative that articulates its commitment to provide cutting-edge solutions focused on delivering streamlined and accelerated clinical trials, increasing certainty from study design to data lock.

January 22, 2024
·
2 min read
Tilak Healthcare Announces Positive Results From Its TIL002 Study Using the OdySight® App, Which Allows Patients With Retinal Diseases to Monitor Their Vision Themselves

Tilak Healthcare, a leader in the field of digital health solutions for monitoring chronic ophthalmic diseases, announces positive results from its TIL002 clinical trial aimed at validating the OdySight® mobile app as a tool allowing patients to measure their visual acuity at home by themselves.

January 22, 2024
·
4 min read
FDA

Inspire(R) 3D Printed Trabecular PEEK(TM) With HAFUSE(R) Lumbar Interbody System Cleared by FDA

Curiteva announced FDA 510(k) clearance of the Inspire 3D Printed Trabecular PEEK Lumbar Interbody Fusion System for use in anterior, transforaminal, posterior, and lateral lumbar interbody fusion procedures.

January 22, 2024
·
2 min read
Business

ReiThera Srl, The Ragon Institute and IAVI Announce Collaboration to Advance Highly Networked T Cell HIV Vaccine Candidate Towards Phase I Clinical Evaluation

ReiThera Srl, the Ragon Institute of Mass General, MIT, and Harvard, and IAVI are pleased to announce a collaboration to develop a novel HIV vaccine candidate that will be composed of ReiThera’s GRAd vector and HIV T cell epitopes identified by the Ragon Institute, funded by the Bill & Melinda Gates Foundation.

January 22, 2024
·
6 min read